What is BioLineRx Ltd. (BLRX)?

BioLineRx Ltd. (BLRX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BLRX?

The current price of BLRX is $2.00. Prices are updated in real time on Stocks360.

What is BLRX's price-to-earnings (PE) ratio?

BLRX's trailing twelve-month PE ratio is -1.14, based on current price and earnings per share data available on Stocks360.

What is BLRX's market capitalization?

BLRX's market capitalization is $9,631,286.00, placing it in the small-cap tier.

BioLineRx Ltd. (BLRX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$2.00

Market Cap

$9.63M

PE (TTM)

-1.14

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.70

Day Range

$1.94 – $2.04

52-wk Range

$1.94 – $3.95

Avg Volume

N/A

Volume

4.04K

BioLineRx Ltd. (BLRX) is a publicly traded company in the Healthcare sector. Latest price: $2.00. Market cap $9.63M. Trailing PE -1.14. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $3.50 2026-10-28 · $2.00 (-42.86%)

Earnings

Most Recent

Aug 31, 2026

EPS $-0.77 vs est. $-0.15

Missed by $0.62

Next Earnings

Nov 23, 2026

EPS estimate $-0.39

Proprietary Signals

Signal snapshot temporarily unavailable.

About BioLineRx Ltd.

BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore M…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.14×
P/S (TTM)	7.54×
P/B	0.69×
PEG	0.00×
P/FCF (TTM)	-0.96×
EV / EBITDA	-1.23×
EV / Sales	9.93×
Earnings Yield	-85.36%
Free Cash Flow Yield	-103.91%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$13.90M
Revenue (TTM)	$1.40M
Net Income (TTM)	-$9.01M
Free Cash Flow (TTM)	-$9.93M
Net Debt	$3.35M
Working Capital	$2.65M
Gross Margin	69.79%
Operating Margin	-874.34%
Net Margin	-574.17%
Return on Equity	-47.22%
Return on Invested Capital	-50.11%